Literature DB >> 33649111

Omadacycline compared to vancomycin when combined with germinants to disrupt the life cycle of Clostridioides difficile.

Noah Budi1, Jared J Godfrey2, Nasia Safdar2, Sanjay K Shukla3, Warren E Rose4.   

Abstract

Clostridioides difficile (C. difficile) infections (CDI) are commonly treated with antibiotics that do not impact the dormant spore form of the pathogen. CDI-directed antibiotics, such as vancomycin and metronidazole, can destroy the vegetative form of C. difficile and protective microbiota. After treatment, spores can germinate into vegetative cells causing clinical disease relapse and further spore shedding. This in vitro study compares the combination of germinants with vancomycin or omadacycline to antibiotics alone in eradicating C. difficile spores and vegetative cells. Among the four strains in this study, omadacycline minimum inhibitory concentrations (0.031-0.125 mg/L) were lower than vancomycin (1-4 mg/L). Omadacycline nor vancomycin in media alone reduced spore counts. In three of the four strains, including the epidemic ribotype 027, spore eradication with germinants was 94.8-97.4% with vancomycin and 99.4-99.8% with omadacycline (p<0.005). In ribotype 012, either antibiotic combined with germinants resulted in 100% spore eradication at 24 hours. The addition of germinants with either antibiotic did not result in significant toxin A or B production, which were below the limit of detection (<1.25 ng/mL) by 48 hours. Limiting the number of spores present in patient GI tracts at the end of therapy may be effective at preventing recurrent CDI and limiting spore shedding in the healthcare environment. These results with germinants warrant safety and efficacy evaluations in animal models.
Copyright © 2021 American Society for Microbiology.

Entities:  

Year:  2021        PMID: 33649111      PMCID: PMC8092874          DOI: 10.1128/AAC.01431-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline.

Authors:  Jimmy Flarakos; Yancy Du; Helen Gu; Lai Wang; Heidi J Einolf; Dung Y Chun; Bing Zhu; Natalia Alexander; Adrienne Natrillo; Imad Hanna; Lillian Ting; Wei Zhou; Kiran Dole; Haiying Sun; Steven J Kovacs; Daniel S Stein; S Ken Tanaka; Stephen Villano; James B Mangold
Journal:  Xenobiotica       Date:  2016-08-08       Impact factor: 1.908

2.  Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile.

Authors:  S Stubbs; M Rupnik; M Gibert; J Brazier; B Duerden; M Popoff
Journal:  FEMS Microbiol Lett       Date:  2000-05-15       Impact factor: 2.742

3.  Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole.

Authors:  Brittany B Lewis; Charlie G Buffie; Rebecca A Carter; Ingrid Leiner; Nora C Toussaint; Liza C Miller; Asia Gobourne; Lilan Ling; Eric G Pamer
Journal:  J Infect Dis       Date:  2015-04-28       Impact factor: 5.226

4.  Evaluation of hospital room assignment and acquisition of Clostridium difficile infection.

Authors:  Megan K Shaughnessy; Renee L Micielli; Daryl D DePestel; Jennifer Arndt; Cathy L Strachan; Kathy B Welch; Carol E Chenoweth
Journal:  Infect Control Hosp Epidemiol       Date:  2011-03       Impact factor: 3.254

5.  Effective and reduced-cost modified selective medium for isolation of Clostridium difficile.

Authors:  Michelle M Nerandzic; Curtis J Donskey
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

6.  Effects of endogenous D-alanine synthesis and autoinhibition of Bacillus anthracis germination on in vitro and in vivo infections.

Authors:  Matthew T McKevitt; Katie M Bryant; Salika M Shakir; Jason L Larabee; Steven R Blanke; Julie Lovchik; C Rick Lyons; Jimmy D Ballard
Journal:  Infect Immun       Date:  2007-10-08       Impact factor: 3.441

7.  Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine.

Authors:  Casey M Theriot; Alison A Bowman; Vincent B Young
Journal:  mSphere       Date:  2016-01-06       Impact factor: 4.389

8.  Short- and long-term effects of oral vancomycin on the human intestinal microbiota.

Authors:  Sandrine Isaac; Jose U Scher; Ana Djukovic; Nuria Jiménez; Dan R Littman; Steven B Abramson; Eric G Pamer; Carles Ubeda
Journal:  J Antimicrob Chemother       Date:  2016-10-05       Impact factor: 5.790

9.  Omadacycline Gut Microbiome Exposure Does Not Induce Clostridium difficile Proliferation or Toxin Production in a Model That Simulates the Proximal, Medial, and Distal Human Colon.

Authors:  Ines B Moura; Anthony M Buckley; Duncan Ewin; Sharie Shearman; Emma Clark; Mark H Wilcox; Caroline H Chilton
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

10.  In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile.

Authors:  Khurshida Begum; Eugénie Bassères; Julie Miranda; Chris Lancaster; Anne J Gonzales-Luna; Travis J Carlson; Tasnuva Rashid; David W Eyre; Mark H Wilcox; M Jahangir Alam; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

View more
  2 in total

Review 1.  Clostridioides difficile spore germination: initiation to DPA release.

Authors:  Marko Baloh; Joseph A Sorg
Journal:  Curr Opin Microbiol       Date:  2021-11-19       Impact factor: 7.934

Review 2.  What's new and notable in bacterial spore killing!

Authors:  Peter Setlow; Graham Christie
Journal:  World J Microbiol Biotechnol       Date:  2021-08-05       Impact factor: 3.312

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.